bioAffinity Technologies, Inc. (BIAF) Research

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

Market snapshot

Symbol
BIAF
Price
$0.84
Day change
+0.65%
Market cap
$3.8M
P/E ratio
-0.24x
52-week range
0.693-13.8
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Next earnings
in 2 months

Peer companies

  • Artelo Biosciences, Inc. (ARTL)
  • Carisma Therapeutics, Inc. (CARM)
  • GT Biopharma, Inc. (GTBP)
  • Lipella Pharmaceuticals Inc. (LIPO)
  • Mobile-health Network Solutions Class A Ordinary Shares (MNDR)
  • Psyence Biomedical Ltd. (PBM)
  • Protagenic Therapeutics, Inc. (PTIX)
  • Revelation Biosciences, Inc. (REVB)

Recent insider activity

  • Rios Roberto — trade (0 shares) on 2025-08-12
  • Oppenheimer John J. — trade (0 shares) on 2025-08-12
  • Reveles Xavier Trinidad — A-Award (21604 shares) on 2025-01-10
  • GIRGENTI STEVEN — A-Award (14814 shares) on 2025-01-10
  • Zannes Maria — A-Award (37037 shares) on 2025-01-10

Open bioAffinity Technologies, Inc. (BIAF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.